JACOBIO-B(01167) presented preclinical data on the Pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

JACOBIO-B (01167) announcement has been released. The company presented the preclinical data of the Pan-KRAS inhibitor JAB-23E73 titled "Preclinical study of the orally bioavailable, potent pan-KRAS (oncogenic-driven/switch) inhibitor JAB-23E73" in abstract and poster form at the 2025 AACR-NCI-EORTC Conference held at the Hynes Convention Center in Boston, Massachusetts, USA from October 22 to October 26, 2025. The JAB-23E73 abstract (without poster) was released through the conference application on Wednesday, October 22, 2025, at 12:00 pm Eastern Time and will also be published as complimentary content in the AACR journal "Molecular Cancer Therapeutics". The JAB-23E73 poster presentation will take place from 12:30 pm to 4:00 pm on October 23, 2025, Eastern Time. JAB-23E73 is a highly potent and orally bioavailable Pan-KRAS (oncogenic-driven/switch) inhibitor with strong selectivity for KRAS, avoiding inhibition of HRAS and NRAS. Data shows that JAB-23E73 demonstrates excellent antitumor activity in various cancer types with different KRAS driver mutations or amplifications; it effectively induces tumor regression in KRAS-driven mouse tumor models without significant weight changes, indicating good tolerability and a wide therapeutic window; JAB-23E73 has favorable pharmacokinetic characteristics for oral administration, regulating the inhibition of p-ERK in tumors based on its plasma concentration; Phase I clinical trials for advanced solid tumor patients carrying KRAS gene mutations are currently underway in China and the USA (NCT06959615, NCT06973564).